IN THE CLAIMS:

Claims 1-43. (Canceled).

Claim 44. (Previously Presented) A target binding protein, comprising (a) a first polypeptide comprising a first single chain Fv binding site (scFv) joined by a linker to the CL of a VL-CL immunoglobulin domain and (b) a second polypeptide comprising a second single chain Fv binding site (scFv) joined by a linker to the CH of a VH-CH1 immunoglobulin domain, wherein the first and second scFv each form two target binding sites independently, and wherein the VL-CL-linker-scFv associates with the VL-CH1-linker-scFv to form a third Fv binding site;

i. wherein the CL of the third binding site is those of human kappa or lambda,

ii. wherein the CH1 of the third binding site is those of human IgG1, and

iii wherein the first polypeptide and second polypeptide are joined by a S-S bond between the CL of the third binding site, and the linker of the second polypeptide, and wherein cysteine is the fifth amino acid of the second polypeptide linker joined to the carboxyl terminal of CH1 of the third binding site.

Claim 45. (Currently Amended) The target binding protein of claim 1, wherein the first amino acids of the linker joined to the carboxyl terminal of CH1 of the third binding site are ~~EPKSC~~ **the first five amino acids of SEQ ID NO:2**.

Claim 46. (Previously Presented) The target binding protein of claim 1, wherein the three binding sites are to the same epitope.

Claim 47. (Previously Presented) The target binding protein of claim 1, wherein two of the binding sites are the same, and the third is to a different epitope.

Claim 48. (Previously Presented) The target binding protein of claim 1, wherein the three binding sites are to different epitopes.

Claim 49. (Previously Presented) The Fvs of claim 1 are from murine, humanized, or human antibodies.